Antibody Information
General Information of This Antibody
| Antibody ID | ANI0AODFG |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | MLYE4489A |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Lymphocyte antigen 6E (LY6E) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
RG7841 [Phase 1 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
17.76%
|
|||
| Patients Enrolled |
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, histologically or cytologically documented advanced or metastatic breast, ovarian, pancreatic, NSCLC, head and neck squamous cell carcinoma, or gastric cancer in dose escalation, adequate hematologic and end organ function, and measurable disease per RECIST v1.1.
|
||||
| Administration Dosage |
Intravenously at doses of 0.20, 0.40, 0.80, 1.60, or 2.40 mg/kg once every 3 weeks (Q3W).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02092792 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1, open-label study evaluating the safety and tolerability of escalating doses of DLYE5953A in patients with refractory solid tumors.
|
||||
| Primary Endpoint |
The confirmed overall objective response rate was 17.76%. All responders (8/68 patients) had PR,and all had received the RP2D dose of 2.40 mg/kg. This included three patients with MBC, and five patients in the NSCLC expansion cohort (5/25; 20%).
|
||||
| Other Endpoint |
The recommended phase II dose (RP2D) was 2.40 mg/kg Q3W. No dose-limiting toxicities were identified during dose escalation (0.20-2.40 mg/kg; n = 20).
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Eligible participants (≥18 years, ECOG 0-1) must have measurable advanced/metastatic solid tumors with no effective standard therapies. Exclusions: recent anticancer treatments (chemotherapy/radiation within 4 weeks; oral kinase inhibitors within 2 weeks unless toxicity resolves).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02092792 | Clinical Status | PHASE1 | ||
| Clinical Description |
A PHASE I, OPEN-LABEL STUDY EVALUATING THE SAFETY AND TOLERABILITY OF ESCALATING DOSES OF DLYE5953A IN PATIENTS WITH REFRACTORY SOLID TUMORS
|
||||
| Primary Endpoint |
The study evaluates safety through dose-limiting toxicities (Days 1-21) and adverse events (up to 32 months) in patients with advanced solid tumors, while also assessing efficacy and drug exposure.
|
||||
| Other Endpoint |
Key outcomes include total drug exposure (AUC), immunogenicity (anti-DLYE5953A antibodies), and efficacy measures like objective response (RECIST v1.1), duration of response, and progression-free survival (all tracked up to 32 months).
|
||||
References